Polycythaemia vera and Christmas disease with slightly prolonged prothrombin time

Insights

This study found prolonged one-stage prothrombin times, characteristic of factor VII deficiency, in families with Christmas disease and polycythemia vera. These clotting abnormalities were observed in affected individuals and their relatives, suggesting a potential genetic link.

Area of Science:

  • Hematology
  • Clinical Pathology
  • Genetics

Background:

  • Christmas disease (hemophilia B) and polycythemia vera are distinct hematological disorders.
  • The one-stage prothrombin time is a crucial test for assessing blood coagulation.
  • Factor VII deficiency is a rare bleeding disorder affecting blood clotting.

Purpose of the Study:

  • To investigate the association between Christmas disease, polycythemia vera, and prolonged one-stage prothrombin times.
  • To explore the nature of the prothrombin time abnormalities observed in these conditions.

Main Methods:

  • Case reporting of a family with Christmas disease and polycythemia vera.
  • Analysis of one-stage prothrombin times in affected individuals and their siblings.
  • Utilizing "mixing procedures" to assess the interaction of plasma factors.

Main Results:

  • Prolonged one-stage prothrombin times, consistent with factor VII deficiency, were identified in a family member with Christmas disease and another with polycythemia vera.
  • Similar prothrombin time alterations were noted in siblings of the Christmas disease patient.
  • Unrelated patients diagnosed with polycythemia vera also exhibited these clotting time changes.
  • Mixing studies did not demonstrate significant correction of the prolonged prothrombin times, indicating a complex underlying mechanism.

Conclusions:

  • The findings suggest a potential link between factor VII deficiency-like prothrombin time abnormalities and both Christmas disease and polycythemia vera.
  • The observed clotting time changes in relatives and unrelated polycythemia vera cases warrant further investigation into potential genetic or shared etiological factors.
  • The lack of correction in mixing studies highlights the complexity of the observed coagulation defect.

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Disorders of Erythrocytes01:27

Disorders of Erythrocytes

Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...